Indaptus Therapeutics, Inc. announced the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023. Dr. Waltzman joins Indaptus from Molecular Templates. Prior, he served in the c-suite as Chief Medical Officer at Rgenix, Inc. and as Chief Scientific Officer at Jaguar Health.

He spent nine years at Novartis, where he served in several leadership positions, including Global Program Head for Tropical Medicines and Clinical Program Head for several key brands, such as Glivec, Tasigna, and Jakavi.Dr. Waltzman spent the early part of his career as a medical oncologist, serving in two of New York Citys premiere hospitals, Mount Sinai Medical System and St. Vincents Hospital. He earned his M.D. degree at Brown University, where he also earned a bachelors degree in American Literature and holds a Masters in Business Administration from Columbia University Business School.